Omnicell (NASDAQ:OMCL) Issues FY 2024 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 1.650-1.720 for the period, compared to the consensus EPS estimate of 1.370. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q4 guidance to $0.55-$0.62 EPS.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on OMCL shares. Benchmark reaffirmed a “buy” rating and set a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Bank of America reissued a “neutral” rating and issued a $57.00 price objective (up from $44.00) on shares of Omnicell in a research note on Thursday. Craig Hallum upped their target price on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wells Fargo & Company lifted their price target on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $49.14.

Omnicell Trading Up 0.1 %

Shares of NASDAQ:OMCL traded up $0.03 during trading on Friday, reaching $48.67. The stock had a trading volume of 683,792 shares, compared to its average volume of 528,146. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The company has a current ratio of 1.05, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. The firm’s fifty day moving average is $43.26 and its 200 day moving average is $35.17.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The business had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. During the same quarter in the prior year, the firm posted $0.29 earnings per share. The business’s quarterly revenue was down 7.4% compared to the same quarter last year. On average, equities research analysts forecast that Omnicell will post 0.64 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.